Charles Schwab
ZVRA icon

Charles Schwab’s Zevra Therapeutics ZVRA Stock Holding History

Charles Schwab’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.65M Buy
184,818
+22,837
+14% +$254K ﹤0.01% 2694
2026
Q1 		$1.51M Sell
161,981
-18,637
-10% -$168K ﹤0.01% 2786
2025
Q4 		$1.62M Buy
180,618
+22,853
+14% +$216K ﹤0.01% 2795
2025
Q3 		$1.5M Sell
157,765
-4,202
-3% -$42.1K ﹤0.01% 2826
2025
Q2 		$1.43M Buy
161,967
+8,636
+6% +$70.1K ﹤0.01% 2778
2025
Q1 		$1.15M Buy
153,331
+3,827
+3% +$30.4K ﹤0.01% 2790
2024
Q4 		$1.25M Buy
149,504
+28,148
+23% +$240K ﹤0.01% 2830
2024
Q3 		$842K Buy
121,356
+11,038
+10% +$74.9K ﹤0.01% 2973
2024
Q2 		$541K Buy
110,318
+18,908
+21% +$89.6K ﹤0.01% 3165
2024
Q1 		$530K Sell
91,410
-4,720
-5% -$29K ﹤0.01% 3005
2023
Q4 		$630K Buy
96,130
+5,698
+6% +$26.6K ﹤0.01% 2986
2023
Q3 		$436K Hold
90,432
– – ﹤0.01% 3091
2023
Q2 		$461K Buy
90,432
+79,293
+712% +$427K ﹤0.01% 3092
2023
Q1 		$61.3K Hold
11,139
– – ﹤0.01% 3314
2022
Q4 		$51.1K Hold
11,139
– – ﹤0.01% 3354
2022
Q3 		$70K Hold
11,139
– – ﹤0.01% 3262
2022
Q2 		$50K Sell
11,139
-65,098
-85% -$297K ﹤0.01% 3394
2022
Q1 		$384K Hold
76,237
– – ﹤0.01% 3157
2021
Q4 		$665K Buy
76,237
+4,505
+6% +$40.2K ﹤0.01% 3061
2021
Q3 		$670K Hold
71,732
– – ﹤0.01% 3038
2021
Q2 		$920K Buy
+71,732
New +$771K ﹤0.01% 2963

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Charles Schwab's ZVRA Position: Q2 2026 in Review

Charles Schwab increased its Zevra Therapeutics (ZVRA) stake by 14% in Q2 2026, buying an estimated $254K and bringing the position to 184,818 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2694.

Charles Schwab first reported a position in ZVRA in Q2 2021 and has held it in 21 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Charles Schwab held 184,818 shares of Zevra Therapeutics worth $2.65M as of Q2 2026.
  • Charles Schwab bought 22,837 Zevra Therapeutics shares in Q2 2026, an estimated $254K.
  • Zevra Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2694 holding.
  • Charles Schwab first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.